Skip to main content
|

Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma

Short Title: ACCL1931


Enrollment Status: Recruiting

NCT #: NCT05602194

Specialty Area: Pediatric Hematology/Oncology

Conditions Studied: Leukemia; Lymphoma

Age Groups: Child; Adult

Phase: III


Study Information

Summary / Purpose

To determine in a randomized manner whether the addition of levocarnitine prophylaxis to asparaginase-containing regimens will decrease the incidence of conjugated hyperbilirubinemia during ALL induction therapy for adolescents and young adults

Study Type: Interventional
Accepts Healthy Volunteers: No

Who Can Participate

Eligibility Criteria:
  • Children and Adults 15+ years of age
  • Must have newly diagnosed B-cell acute lymphoblastic leukemia, T-cell acute lymphoblastic leukemia, lymphoblastic lymphoma, or mixed-phenotype acute leukemia/lymphoma

What's Involved

Participation in the study will include:
  • Standard chemotherapy regimens
  • Blinatumomab administered during specific phases of treatment

Principal Investigator

Additional Information

Location: Renown Health, Office of Clinical Research
Address:

1500 E 2nd St. Reno, NV 89502

General Research: 775-982-3646
Oncology Research: 775-982-5050
Email: Renown-CRD@renown.org

Disclaimer: This listing gives you general information about the study and isn't part of the official consent process. If you decide to learn more, the research team will talk with you and check if you meet any additional requirements to join the study.

ER Wait Times

How are wait times calculated?

Our estimated ER wait times reflect the average time from check-in to being seen by a medical professional during triage, where patients are prioritized based on the severity of their condition.

Health & Wellness eNews
Sign Up